Mydecine Innovations Group (OTCMKTS:MYCOF) Stock Price Up 0.2% – Still a Buy?

Mydecine Innovations Group Inc. (OTCMKTS:MYCOF)’s share price shot up 0.2% on Tuesday . The company traded as high as $1.32 and last traded at $1.32. 388 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 2,318 shares. The stock had previously closed at $1.3175.

Mydecine Innovations Group Stock Performance

The firm’s 50 day moving average price is $0.74 and its 200-day moving average price is $0.34.

About Mydecine Innovations Group

Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical‐stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next‐generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.

Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model.